Berlex HRT “not approvable”
Executive Summary
Berlex Labs' hormone replacement therapy Angeliq (drosperinone) deemed "not approvable" by FDA Oct. 17. After public reaction to the Women's Health Initiative study, "it is understandable that it is difficult to assess new HRT preparations," Schering AG maintains. Company's estradiol/levonorgestrel combination patch received a "not approvable" letter Oct. 8 (1"The Pink Sheet" Oct. 14, In Brief)...
You may also be interested in...
Berlex To Submit Angeliq NDA Response In March, Add Cardioprotective Data
Schering AG's Berlex subsidiary expects to complete its response to FDA on its NDA for the hormone replacement therapy Angeliq in March
Schering AG hormone patch
Schering AG estradiol/levonorgestrel transdermal combination patch deemed "not approvable" by FDA Oct. 8, Schering AG says. The NDA, originally filed June 29, 2000, received a previous "not approvable" letter in June 2001 (1"The Pink Sheet" July 9, 2001, p. 19)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.